Confronto

Glepaglutide vs. LL-37

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

597562-32-8

Peso molecolare

nessun dato

4493.33 g/mol

Emivita

nessun dato

Sequenza

nessun dato

LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

LL-37

LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	LL-37
Germania	Non approvato	Solo ricerca
Stati Uniti	Non approvato	Solo ricerca

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and LL-37?: Glepaglutide is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or LL-37?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and LL-37 in Germany and the United States?: Germania: Glepaglutide — Non approvato, LL-37 — Solo ricerca. Stati Uniti: Glepaglutide — Non approvato, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

LL-37

Germania

Non approvato

Solo ricerca

Stati Uniti

Non approvato

Solo ricerca

Frequently asked questions

What is the difference between Glepaglutide and LL-37?

Glepaglutide is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or LL-37?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and LL-37 in Germany and the United States?

Germania: Glepaglutide — Non approvato, LL-37 — Solo ricerca. Stati Uniti: Glepaglutide — Non approvato, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.